Figure 4.
Recurrent disease development in patients with ERBB2-positive DTCs. Patients with Her2 positive tumors received chemotherapy with trastuzumab. Patients with Her2-negative tumors received cytotoxic chemotherapy alone. All patients had ERBB2-positive DTCs. All recurrences detected within 24 months (mean=19) of diagnosis.